Article Sidebar

PDF
Date Published: 11/07/2022
Online Published: 11/07/2022
Abstract Views: 241
Views PDF: 88
DOI: https://doi.org/10.55046/vjrnm.27.452.2017
Issue
No. 27 (2017)
Section
Scientific research
How to Cite
Le, V. P., Bui, A. T., & Bui, N. T. (2022). The value of magnetic resonance spectroscopy in diagnosis of prostate cancer. Vietnamese Journal of Radiology and Nuclear Medicine, 27, 28-32. https://doi.org/10.55046/vjrnm.27.452.2017

The value of magnetic resonance spectroscopy in diagnosis of prostate cancer

Le Van Phuoc1, Bui Anh Thang1, Bui Ngoc Thuan1,
1 Department of Diagnostic Imaging, Cho Ray Hospital

Main Article Content

Abstract

SUMMARY


Purpose: The aim of study was to determine the value of MRS in diagnosis of prostate carcinoma especially for differentiating begnin from malignant lesion of the prostate.
Materials and methods: During a period of 4/2014 to 6/2016, 25 consecutive patients with elevated PSA level or clinical suspiciousness were evaluated with MRS of the prostate. The results were confirmed by TRUS-guided biopsy. We compare two groups (prostate carcinoma/PCa and prostate non caricnoma/PNCa) by variant: mean of
the choline plus creatine -to- citrate. Analyzing ROC curve to find the value of MRS in differentiating begnin from malignant tissue of the prostate.
Results: Patients range in age from 40 to 89 years (mean 71 ± 12 year). 08 patients were confirmed to have PNCa (32%), whereas 17 patients had PCa (68%). The mean of (Cho+ Cr)/Ci values for PNCa and PCa were 0.50±
0.31 and 2.64± 1.22 respectively. The mean of (Cho+Cr)/ Ci value of PCa was significantly higher than PNCa (p<0.05). On ROC curve, using discrimination threshold of (Cho+Cr)/
Ci is 0.84, the MRS provided a sensitivity of 94.1%, specificity of 87.5% for differentiating NPCa from PCa.
Conclusion: Magnetic Resonance Spectroscopy of the prostate can be use to differentiate begnin from malignant tissue with high accuracy.

Article Details

Keywords

Prostatic carcinoma, non-carcinoma, Magnetic resonance spectroscopy, TRUS

References

TÀI LIỆU THAM KHẢO
1. Amita Shukla-Dave. “Detection of prostate cancer with MR Spectroscopy Imaging: An expanded with paradigm incorporating Polyamines’’. RSNA. Radiology: Volume 245: Number 2-November 2007.
2. Arumugam Rajesh et al. “MR imaging and MR spectroscopic imaging of prostate cancer”. Magn Reson Imaging Clin N Am 12 (2004) 557 - 579.
3. Daniel M. Cornfeld et al. “MR Imaging of the Prostate: 1.5T versus 3T”. Magn Reson Imaging Clin N Am 15 (2007) 433 - 448.
4. Jaime Araujo Oliveira Neto et al, “Multiparametric Magnetic Resonance Imaging of the Prostate”. Magn Reson Imaging Clin N Am 21 (2013) 4090 - 426.
5. John Kurhanewicza et al. “Multiparametric magnetic resonance imaging in prostate cancer: present and future”. NIH-PA 2008 January ; 18(1): 71 - 77.
6. Peter R. Carroll, Fergus V. Coakley, John Kurhanewicz. “Magnetic Resonance Imaging and Spectroscopy of Prostate Cancer”. Rev Urol. 2006;8(suppl 1):S4-S10.
7. Nagarajan et al. “MR Spectroscopic Imaging of Peripheral Zone in Prostate Cancer Using a 3T MRI Scanner: Endorectal versus External Phased Array Coils”. Magnetic Resonance Insights 2013:6 510 - 58.
8. Riches SF (2015). “Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters”, European Radiology, 25(5), pp.1247-1256.
9. Yuranga Weerakkody and Paresh K Desai et al. “MR spectroscopy in prostate cancer”. Radiopedia.